Tempus AI's Strategic Push to Expand Beyond Oncology
TEM extends its AI tools beyond oncology, adding FDA-cleared cardiac and ECG software plus key acquisitions to deepen its diagnostic reach.
| Ticker |
TEM
|
| CIK | 0001717115 |
| SIC | 7370 |
| Sector | Services |
| Industry Category | Computer Software |
| Industry Group | Services – Computer Programming And Data Processing |
| Address | 600 WEST CHICAGO AVENUE, SUITE 510, CHICAGO, IL, 60654 |
| Website | www.tempus.com |
| Phone | 800-976-5448 |
| CEO | Eric Lefkofsky |
| Employees | N/A |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Tempus AI's Strategic Push to Expand Beyond OncologyTEM extends its AI tools beyond oncology, adding FDA-cleared cardiac and ECG software plus key acquisitions to deepen its diagnostic reach. How Tempus AI’s Expanded Breast Cancer Data Research At Tempus AI (TEM) Has Changed Its Investment StoryTempus AI recently announced that ten of its scientific and clinical research abstracts were accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, showcasing work that integrates multimodal real-world, genomic, and transcriptomic data to better understand breast cancer treatment response and resistance. A key insight from these studies is the use of large-scale longitudinal real-world data to refine risk stratification and identify patient subgroups who might benefit... Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer SymposiumCHICAGO, December 09, 2025--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Antonio, Texas. 5 Tech Stocks Insiders Are Selling (But Smart Investors Are Loading Up)Insiders are selling tech stocks after the massive rally in 2025. Some are up by 300% or more, providing attractive exits for execs. Investors shouldn't follow. Tempus AI: Data Flywheel and MRD Expansion Reshape the OutlookTempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner. |